These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7200396)

  • 21. Nephrotoxicity of cis-platinum (II) dichlorodiammine.
    Stark JJ; Howel SB
    Clin Pharmacol Ther; 1978 Apr; 23(4):461-6. PubMed ID: 415836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute renal failure following intraperitoneal injection of cis-diamminedichloroplatinum.
    Hosokawa S; Kohira S; Tomotoshi T
    Urol Int; 1984; 39(4):246-9. PubMed ID: 6541388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin.
    Lam M; Adelstein DJ
    Am J Kidney Dis; 1986 Sep; 8(3):164-9. PubMed ID: 3752072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study.
    Yoshida T; Niho S; Toda M; Goto K; Yoh K; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y
    Jpn J Clin Oncol; 2014 Apr; 44(4):346-54. PubMed ID: 24503028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Magnesium protects against cisplatin-induced acute kidney injury without compromising cisplatin-mediated killing of an ovarian tumor xenograft in mice.
    Solanki MH; Chatterjee PK; Xue X; Gupta M; Rosales I; Yeboah MM; Kohn N; Metz CN
    Am J Physiol Renal Physiol; 2015 Jul; 309(1):F35-47. PubMed ID: 25947343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding the Risk Factors and Long-Term Consequences of Cisplatin-Associated Acute Kidney Injury: An Observational Cohort Study.
    Bhat ZY; Cadnapaphornchai P; Ginsburg K; Sivagnanam M; Chopra S; Treadway CK; Lin HS; Yoo G; Sukari A; Doshi MD
    PLoS One; 2015; 10(11):e0142225. PubMed ID: 26556481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platinum nephrotoxicity.
    Madias NE; Harrington JT
    Am J Med; 1978 Aug; 65(2):307-14. PubMed ID: 99034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ototoxicity of cis-diamminedichloroplatinum.
    Vodvárka P; Foukalová J; Mrázek J; Philippová J
    Neoplasma; 1985; 32(2):229-38. PubMed ID: 4039797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of para-aminobenzoic acid on the pharmacokinetics and urinary excretion of cis-diamminedichloroplatinum(II) in rats.
    Esposito M; Vannozzi M; Viale M; Pellecchia C; Civalleri D; Gogioso L
    Anticancer Res; 1995; 15(6B):2541-7. PubMed ID: 8669820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study.
    Gaspari F; Cravedi P; Mandalà M; Perico N; de Leon FR; Stucchi N; Ferrari S; Labianca R; Remuzzi G; Ruggenenti P
    Nephron Clin Pract; 2010; 115(2):c154-60. PubMed ID: 20407275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cisplatin pharmacokinetics in a patient with renal dysfunction.
    Prestayko AW; Luft FC; Einhorn L; Crooke ST
    Med Pediatr Oncol; 1978; 5(1):183-8. PubMed ID: 745586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal protective effect of a hydration supplemented with magnesium in patients receiving cisplatin for head and neck cancer.
    Kimura T; Ozawa T; Hanai N; Hirakawa H; Suzuki H; Hosoi H; Hasegawa Y
    J Otolaryngol Head Neck Surg; 2018 Feb; 47(1):10. PubMed ID: 29394952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cis-dichlorodiammineplatinum(II) alone and combined with DTIC for treatment of disseminated malignant melanoma.
    Goodnight JE; Moseley HS; Eilber FR; Sarna G; Morton DL
    Cancer Treat Rep; 1979; 63(11-12):2005-7. PubMed ID: 393385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic study of Cis-dichlorodiammine platinum II, in children after rapid infusion.
    Cano JP; Catalin J; Rigault JP; Bues-Charbit M; Placidi M; Raybaud C; Bernard JL
    Biomedicine; 1981 Dec; 34(3):146-53. PubMed ID: 7199945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lower Blood Pressure-Induced Renal Hypoperfusion Promotes Cisplatin-Induced Nephrotoxicity.
    Mizuno T; Hayashi T; Shimabukuro Y; Murase M; Hayashi H; Ishikawa K; Takahashi K; Yuzawa Y; Yamada S; Nagamatsu T
    Oncology; 2016; 90(6):313-20. PubMed ID: 27225867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of montelukast on cisplatin-induced experimental acute renal failure.
    Teslariu O; Nechifor M; Plămădeală P; Miron IC
    Rev Med Chir Soc Med Nat Iasi; 2014; 118(3):612-7. PubMed ID: 25341273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cisplatin nephrotoxicity. Correlation with plasma platinum concentrations.
    Kelsen DP; Alcock N; Young CW
    Am J Clin Oncol; 1985 Feb; 8(1):77-80. PubMed ID: 4039530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quiescent LLC-PK1 cells as a model for cis-diamminedichloroplatinum(II) nephrotoxicity and modulation by thiol rescue agents.
    Montine TJ; Borch RF
    Cancer Res; 1988 Nov; 48(21):6017-24. PubMed ID: 2458831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cis-Dichlorodiammine platinum and adriamycin therapy for advanced gynecological and genitourinary neoplasms.
    Ostrow S; Egorin MJ; Hahn D; Markus S; Leroy A; Chang P; Klein M; Bachur NR; Wiernik PH
    Cancer; 1980 Oct; 46(8):1715-21. PubMed ID: 7191768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation and involvement of p53 in cisplatin-induced nephrotoxicity.
    Wei Q; Dong G; Yang T; Megyesi J; Price PM; Dong Z
    Am J Physiol Renal Physiol; 2007 Oct; 293(4):F1282-91. PubMed ID: 17670903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.